A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.
Collin
C
C
Royal Berkshire and Battle Hospitals NHS Trust, London Road, Reading, Berkshire RG1 5AN, UK. christine.collin@royalberkshire.nhs.uk
Ehler
E
E
Waberzinek
G
G
Alsindi
Z
Z
Davies
P
P
Powell
K
K
Notcutt
W
W
O'Leary
C
C
Ratcliffe
S
S
Nováková
I
I
Zapletalova
O
O
Piková
J
J
Ambler
Z
Z
D002185:Cannabidiol; D004311:Double-Blind Method; D013759:Dronabinol; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000150:complications / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
D004338:Drug Combinations; D009465:Neuromuscular Agents; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols